Basel

Switzerland-based Roche has agreed to acquire French biotechnology firm Trophos, in a bid to expand its neuromuscular disease portfolio.

As part of the deal, Roche will pay an upfront cash payment of €120m to Trophos’s shareholders, as well as additional contingent payments of up to €350m based on achievement of certain predetermined milestones.

Established in 1999, Trophos developed a cholesterol-oxime based chemistry platform. It was supported by a syndicate of private equity funds including ACG Management, OTC Agregator, Amundi Private Equity Funds, Turenne Capital, Sofipaca and Vesale Partners, as well as the French Muscular Dystrophy Association (AFM).

Roche chief medical officer Dr Sandra Horning said: "This acquisition highlights Roche’s commitment to developing medicines for spinal muscular atrophy, a serious disease with no effective treatment.

"Roche will pay an upfront cash payment of €120m to Trophos’s shareholders, as well as additional contingent payments of up to €350m based on achievement of certain predetermined milestones."

"We will build on the work done by Trophos and the French Muscular Dystrophy Association to advance the development of olesoxime and to bring it to people who live with this devastating condition as quickly as possible."

Trophos’s portfolio includes proprietary screening platform generated olesoxime (TRO19622), which is being developed for spinal muscular atrophy (SMA), a genetic neuromuscular disease in children.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Olesoxime is an investigational medicine, which is designed to protect the health of motor nerve cells.

According to Roche, olesoxime’s Phase II clinical trial in SMA demonstrated a beneficial effect on the maintenance of neuromuscular function in individuals with Type II and non-ambulatory Type III SMA, as well as reduced medical complications associated with the disease.

Trophos CEO Christine Placet said: "SMA is a grievous disease with a huge impact on the daily life of patients and their families, who are currently left only with supportive care."


Image: Roche’s Basel site. Photo: courtesy of F Hoffmann-La Roche Ltd.